Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 5, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The material change reported is a transfer of 18,044 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on May 30, 2006, and was advised to the Company on June 5, 2006.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b). The GSK Trust is identified as a discretionary trust where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries.
Key Facts for Investor Verification
- 18,044 Ordinary Shares were transferred from the GSK Trust to employee plan participants on May 30, 2006.
- Directors Dr J-P Garnier, Mr J S Heslop, and Dr M Slaoui hold interests in the GSK Trust shares in the same capacity as other employees.
- The filing was signed by Victoria Whyte as the Authorised Signatory on June 5, 2006.
- No financial performance data is included in this specific filing.